Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Pamela Munster, Ian E. Krop, Patricia LoRusso, Cynthia Ma, Barry A. Siegel, Anthony F. Shields, István Molnár, Thomas J. Wickham, Joseph Reynolds, Karen Campbell, Bart S. Hendriks, Bambang S. Adiwijaya, Elena Geretti, Victor Moyo, Kathy D. Miller
Dive into the research topics of 'Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study'. Together they form a unique fingerprint.